Making up your mind: Interneurons in development and disease

  • Autism Research
Speaker Gordon Fishell, Ph.D.
Harvard University
Date & Time


Location

Gerald D. Fischbach Auditorium
160 5th Avenue
New York, NY 10010 United States

Autism Research

Autism Research lectures bring together scientists and scholars to discuss diverse and important topics related to autism.

Video Thumbnail

By clicking to watch this video, you agree to our privacy policy.

On 27 January 2016, Gordon Fishell described his investigations of the developmental and genetic origins of interneuron development.

His talk was part of the Simons Foundation Autism Research lecture series.

About the Lecture

Interneurons within the brain, in the cortex and hippocampus in particular, are central for normal brain function, and conversely, dysfunction of these cell types is thought to result in developmental neurological disorders. The Fishell laboratory combines genetic and physiological approaches to examine the origins of these populations and their integration into brain circuitry.

In this lecture, Gordon Fishell described his investigations of the developmental and genetic origins of interneuron development. This process begins with their specification, during which genetic programs initiated within progenitors relegate interneurons into specific cardinal classes. Subsequent to this, neuronal activity is fundamental for both the laminar positioning as well as the dendritic and axonal arborization in at least some interneuron subtypes. Fishell’s findings suggest that sensory information complements earlier established genetic programs to shape the way interneuronal subtypes integrate into nascent cortical circuits. Importantly, many of the genes involved in the maturation of interneurons appear to also be implicated in neuropsychiatric diseases, including autism and schizophrenia.

About the Speaker

Gordon J. Fishell, Ph.D., is associate director of the NYU Neuroscience Institute, Julius Raines Professor of Neuroscience and Physiology, and director of the Graduate Program in Neuroscience and Physiology at New York University (NYU) School of Medicine. Fishell is a long-standing member of the NYU School of Medicine community, having joined the developmental genetics program in the Skirball Institute of Biomolecular Medicine in 1994. In 2006, he launched the Smilow Neuroscience Program, and in 2011 he became associate director of the then-newly-formed NYU Neuroscience Institute.

Past Lectures

How emotions shape our memories

Kelsey C. Martin, M.D., Ph.D.Director, SFARI
Director, Simons Foundation Neuroscience Collaborations
Leonard Mlodinow, Ph.D.Physicist and Author

Have you ever contemplated the difference between a feeling, a thought and a memory? And how do all these things fit together in making us who we are?

Leonard Mlodinow is a theoretical physicist and best-selling author. In his latest book, “Emotional: How Feelings Shape Our Thinking,” he unpacks the role emotions play in our thinking and mental well-being.

Kelsey Martin, director of the Simons Foundation Autism Research Initiative (SFARI) and the foundation’s neuroscience collaborations, has spent much of her career as a neuroscientist seeking to understand better how experiences change brain connectivity to store long-term memories.

What do we mean by ‘autism risk genes’?

David Ledbetter, Ph.D.
Chief Clinical Officer, Dascena

Joseph Buxbaum, Ph.D.
Director, Seaver Autism Center
Professor, Psychiatry, Neuroscience, Genetics and Genomic Sciences
Vice Chair for Research and Vice Chair for Mentoring, Psychiatry, Icahn School of Medicine at Mount Sinai

Heather Mefford, M.D., Ph.D.
Full Member, St. Jude Children’s Research Hospital

David Ledbetter and Joseph Buxbaum discussed whether there are genes for which mutations confer risk specific to autism or whether these genes are really conferring general risk of disrupted brain development. The discussion was moderated by Heather Mefford.

Small molecules, genes and antisense oligonucleotides: Industry perspectives on treatment development for ASD

Federico Bolognani, M.D., Ph.D.
Vice President, Head of Clinical Science, Axial Therapeutics

Stuart Cobb, Ph.D.
Chief Scientific Officer, Neurogene; Research Fellow, University of Edinburgh

Yael Weiss, M.D., Ph.D.
Vice President, Business Development, Ultragenyx

Randy Carpenter, M.D.
Chief Medical Officer, Rett Syndrome Research Trust; Co-Founder, Allos Pharma

Federico Bolognani, Stuart Cobb, and Yael Weiss joined a panel to discuss new industry developments on the use of small molecules, gene therapy and antisense oligonucleotides as treatment approaches for autism spectrum disorders (ASD). The panel discussion was moderated by Randall Carpenter.

Subscribe to our newsletter and receive SFARI funding announcements and news